ES2821407T3 - Compuestos de piperidina sustituidos con indol como agentes degradantes de los receptores de estrógenos - Google Patents

Compuestos de piperidina sustituidos con indol como agentes degradantes de los receptores de estrógenos Download PDF

Info

Publication number
ES2821407T3
ES2821407T3 ES17769483T ES17769483T ES2821407T3 ES 2821407 T3 ES2821407 T3 ES 2821407T3 ES 17769483 T ES17769483 T ES 17769483T ES 17769483 T ES17769483 T ES 17769483T ES 2821407 T3 ES2821407 T3 ES 2821407T3
Authority
ES
Spain
Prior art keywords
compound
group
pmol
mmol
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17769483T
Other languages
English (en)
Spanish (es)
Other versions
ES2821407T8 (es
Inventor
Jianyu Lu
Charles Z Ding
Lihong Hu
Huijun He
Shuhui Chen
Jiaqiang Dong
Tie-Lin Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Luoxin Biotechnology Shanghai Co Ltd
Shandong Luoxin Pharmaceutical Group Co Ltd
Shandong Luoxin Pharmaceutical Co Ltd
Original Assignee
Luoxin Biotechnology Shanghai Co Ltd
Shandong Luoxin Pharmaceutical Group Co Ltd
Shandong Luoxin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luoxin Biotechnology Shanghai Co Ltd, Shandong Luoxin Pharmaceutical Group Co Ltd, Shandong Luoxin Pharmaceutical Co Ltd filed Critical Luoxin Biotechnology Shanghai Co Ltd
Application granted granted Critical
Publication of ES2821407T3 publication Critical patent/ES2821407T3/es
Publication of ES2821407T8 publication Critical patent/ES2821407T8/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
ES17769483T 2016-03-25 2017-03-24 Compuestos de piperidina sustituidos con indol como agentes degradantes de los receptores de estrógenos Active ES2821407T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610180518 2016-03-25
CN201610867918 2016-09-29
PCT/CN2017/078139 WO2017162206A1 (zh) 2016-03-25 2017-03-24 作为雌激素受体降解剂的吲哚并取代哌啶类化合物

Publications (2)

Publication Number Publication Date
ES2821407T3 true ES2821407T3 (es) 2021-04-26
ES2821407T8 ES2821407T8 (es) 2022-02-02

Family

ID=59899253

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17769483T Active ES2821407T3 (es) 2016-03-25 2017-03-24 Compuestos de piperidina sustituidos con indol como agentes degradantes de los receptores de estrógenos

Country Status (11)

Country Link
US (1) US10519143B2 (cg-RX-API-DMAC10.html)
EP (1) EP3434668B1 (cg-RX-API-DMAC10.html)
JP (1) JP6790222B2 (cg-RX-API-DMAC10.html)
KR (1) KR102111792B1 (cg-RX-API-DMAC10.html)
CN (1) CN108884035B (cg-RX-API-DMAC10.html)
AU (1) AU2017239348B2 (cg-RX-API-DMAC10.html)
CA (1) CA3018801C (cg-RX-API-DMAC10.html)
ES (1) ES2821407T3 (cg-RX-API-DMAC10.html)
RU (1) RU2722441C2 (cg-RX-API-DMAC10.html)
SG (1) SG11201808363TA (cg-RX-API-DMAC10.html)
WO (1) WO2017162206A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111032627B (zh) 2017-09-25 2023-10-20 罗欣健康科技发展(北京)有限公司 一种雌激素受体抑制剂的晶型及其制备方法
AU2019321588C1 (en) 2018-08-17 2026-05-14 Genentech, Inc. Diagnostic and therapeutic methods for the treatment of breast cancer
EP3889136B1 (en) * 2018-11-28 2024-12-18 Luoxin Pharmaceutical (Shanghai) Co., Ltd. Salt form of estrogen receptor downregulator, crystalline form thereof, and preparation method therefor
AU2019400398B2 (en) * 2018-12-17 2024-10-03 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Estrogen receptor antagonist
CN116891461B (zh) * 2022-03-30 2026-05-15 罗欣药业(上海)有限公司 一种serd中间体的合成方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW397821B (en) * 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US20100317635A1 (en) * 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
GB0917571D0 (en) 2009-10-07 2009-11-25 Karobio Ab Novel estrogen receptor ligands
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
US9499538B2 (en) * 2012-03-20 2016-11-22 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
SG11201607334YA (en) * 2014-03-13 2016-10-28 Hoffmann La Roche Therapeutic combinations with estrogen receptor modulators
MA39740A (fr) * 2014-03-13 2017-01-18 Hoffmann La Roche Méthodes et compositions pour moduler des mutants du récepteur des oestrogènes

Also Published As

Publication number Publication date
CA3018801A1 (en) 2017-09-28
RU2018135203A3 (cg-RX-API-DMAC10.html) 2020-04-27
RU2722441C2 (ru) 2020-06-01
CN108884035A (zh) 2018-11-23
US20190106414A1 (en) 2019-04-11
SG11201808363TA (en) 2018-10-30
US10519143B2 (en) 2019-12-31
EP3434668B1 (en) 2020-08-26
RU2018135203A (ru) 2020-04-27
EP3434668A4 (en) 2019-08-14
ES2821407T8 (es) 2022-02-02
CN108884035B (zh) 2020-03-13
WO2017162206A1 (zh) 2017-09-28
EP3434668A1 (en) 2019-01-30
KR102111792B1 (ko) 2020-05-18
AU2017239348B2 (en) 2020-03-12
JP2019512550A (ja) 2019-05-16
JP6790222B2 (ja) 2020-11-25
CA3018801C (en) 2020-06-23
KR20180128456A (ko) 2018-12-03
HK1256936A1 (zh) 2019-10-04
AU2017239348A1 (en) 2018-11-15

Similar Documents

Publication Publication Date Title
ES2988855T3 (es) Compuesto macrocíclico que sirve como inhibidor de wee1 y aplicaciones del mismo
TWI504604B (zh) 雜環化合物及其用途
BR112019014756A2 (pt) Composto, composição farmacêutica e uso dos mesmos
ES2927352T3 (es) Inhibidores selectivos de HDAC6, método de preparación de los mismos y aplicación de los mismos
CN110139863B (zh) 作为雌激素受体降解剂的吲哚并取代哌啶类化合物
TWI597276B (zh) 胺基甲酸酯/尿素衍生物
US10519143B2 (en) Substituted-indole-compounds as estrogen receptor down-regulators
ES2615052T3 (es) Compuesto de benzotiazolona
WO2019134662A1 (zh) 作为csf-1r抑制剂的杂环化合物及其应用
AU2018228555A1 (en) Azetidine derivative
US10081600B2 (en) 2-alkoxy-11-hydroxyaporphine derivatives and uses thereof
US20250333371A1 (en) Compounds
WO2022171088A1 (zh) 吡唑并[3,4-d]嘧啶-3-酮衍生物
ES2642003T3 (es) Sales de un compuesto de benzotiazolona como agonistas del adreno-receptor beta-2
EA049475B1 (ru) Дейтерированные ингибиторы dhodh
WO2024099404A1 (zh) 一种含氮螺环类化合物、药物组合物以及其用途
TW202504897A (zh) 取代的苯並七元環化合物及其應用
HK1256936B (en) Substituted-indole compounds as estrogen receptor down-regulators
EP4255893A1 (en) Compounds and their use for treating neuropathic pain
BR112020006185B1 (pt) Compostos ou sais farmaceuticamente aceitáveis dos mesmos e uso dos mesmos
BR112020006185A2 (pt) derivado de anel fundido utilizado como inibidor de receptor a2a
BR112019014152B1 (pt) Compostos inibidores seletivos de hdac6, composição farmacêutica compreendendo os referidos compostos e uso dos mesmos
CN103319456A (zh) 二氢吡啶类化合物、其组合物、制备方法和用途